-
Nutrients Dec 2017(1) Background: Dietary fiber intake may provide beneficial effects on the components of metabolic syndrome (MetS); however, observational studies reported inconsistent... (Meta-Analysis)
Meta-Analysis Review
(1) Background: Dietary fiber intake may provide beneficial effects on the components of metabolic syndrome (MetS); however, observational studies reported inconsistent results for the relationship between dietary fiber intake and MetS risk. We conducted a meta-analysis to quantify previous observational studies and a narrative review to summarize mechanisms involved in the potential relationship. (2) Methods: The literature was searched on PubMed and Web of Science until 28 November 2017. A random-effects model was used to calculate the summary risk estimates. Eleven cross-sectional studies and three cohort studies were included in the meta-analysis. Results from the original studies were reported as odds ratios (ORs) or relative ratios (RRs) of the MetS associated with different levels of dietary fiber intake, and the ORs/RRs comparing the highest with lowest categories of the intake were pooled. (3) Results: For the cross-sectional studies, the pooled OR was 0.70 (95% confidence interval (CI): 0.61-0.82) with evidence of high heterogeneity (² = 74.4%, < 0.001) and publication bias ( for Egger's test < 0.001). After removing four studies, results remained significant (OR = 0.67, 95% CI: 0.58-0.78) and the heterogeneity was largely reduced (² = 32.4%, = 0.181). For the cohort studies, the pooled RR was 0.86 (95% CI: 0.70-1.06). (4) Conclusion: Although the meta-analysis suggests an inverse association between dietary fiber intake and risk of MetS, and the association was supported by a wide range of mechanism studies, the findings are limited by insufficient cohort data. More prospective studies are needed to further verify the association between dietary fiber intake and the risk of MetS.
Topics: Dietary Fiber; Humans; Metabolic Syndrome; Odds Ratio; Protective Factors; Recommended Dietary Allowances; Risk Factors
PubMed: 29278406
DOI: 10.3390/nu10010024 -
Nutrients May 2022Metabolic syndrome (MetS) is increasingly prevalent, and the relationship between dietary magnesium and MetS remains controversial. Therefore, we aimed to explore the...
Metabolic syndrome (MetS) is increasingly prevalent, and the relationship between dietary magnesium and MetS remains controversial. Therefore, we aimed to explore the association and dose-response relationship between dietary magnesium intake and MetS and its single component. The sample was adults aged 18 years and above who participated in at least two follow-up surveys in 2009, 2015 and 2018. Food consumption data were collected from three consecutive 24-h dietary recalls. The multivariate Cox proportional risk regression model and restricted cubic spline (RCS) model were used to analyze the association and dose-response relationship between dietary magnesium intake and MetS and its components. In our study, 6104 subjects were included, with a total follow-up of 37,173.36 person-years, and the incidence was 33.16%. Cox regression analysis showed that the multivariable-adjusted Hazard Ratio (HR) for MetS comparing the highest to the lowest quintile of dietary magnesium intake was 0.84 (95% confidence intervals [CI] = 0.71-0.99). Central obesity, elevated TG, elevated blood pressure and elevated blood glucose were reduced by 18%, 41%, 20% and 42%, respectively. The risk of decreased HDL-C was reduced by 23% in the third quintile of dietary magnesium intake, with a slightly increased risk in the highest group. RCS analysis showed that the overall and non-linear associations between dietary magnesium and MetS and its components were statistically significant, the risk of them decreased significantly when magnesium intake was lower than 280 mg/day, and then the curve leveled off or slightly increased.
Topics: Adult; Diet; Humans; Incidence; Magnesium; Metabolic Syndrome; Obesity
PubMed: 35631154
DOI: 10.3390/nu14102013 -
Journal of Medicine and Life 2020Metabolic syndrome (Mets) is a set of metabolic disorders including abdominal obesity, insulin resistance or disorders of glucose absorption and metabolism, lipid...
Metabolic syndrome (Mets) is a set of metabolic disorders including abdominal obesity, insulin resistance or disorders of glucose absorption and metabolism, lipid disorders, and hypertension, which increases the risk of chronic diseases including type 2 diabetes, cardiovascular diseases, cancer, and mortality. Therefore, the present study aimed to determine the trend of Mets and its components in Zahedan, a city located in South-East of Iran, from 2009 to 2017. A total of 761 individuals aged >20 years were followed from 2009 to 2017. The frequency of metabolic syndrome was measured at two-time points based on four criteria: International Diabetes Federation (IDF), National Cholesterol Education Program-Third Adult Treatment Panel (NCEP-ATP III), Third Adult Treatment Panel (ATP III), and American Heart Association and the National Heart Lung and Blood Institute (AHA/NHLBI). The prevalence of Mets ranged from 16.6 (95% CI: 13.9 - 19.2) (ATP III) to 23.70% (95% CI: 20.6 - 26.6) (AHA/NHLBI) in 2009. Accordingly, it increased from 5.2% to 7.3% during the study period using different criteria such that the frequency of Mets varied from 21.8 (95% CI: 18.8 - 24.7) (ATP III) to 31.0% (95% CI: 27.7 - 34.3) (AHA/NHLBI) in 2017. The increasing trend was prominent among females, persons aged <40 years, and those with the lowest educational level. Two components of Mets (abdominal obesity and diabetes) increased in prevalence, whereas elevated blood pressure, hypertriglyceridemia, and low HDL declined. The study revealed an annual increase rate of about 1% in the prevalence of metabolic syndrome. Therefore, the increasing trend of some components of Mets highlights the urgency of addressing these components as health priorities.
Topics: Adult; Female; Follow-Up Studies; Humans; Iran; Logistic Models; Male; Metabolic Syndrome; Middle Aged; Prevalence
PubMed: 33456611
DOI: 10.25122/jml-2020-0052 -
Frontiers in Endocrinology 2022
Topics: Humans; Metabolic Syndrome; Renal Insufficiency, Chronic
PubMed: 36187127
DOI: 10.3389/fendo.2022.1030497 -
Nutrients Apr 2022Metabolic syndrome (MS) is associated with a range of chronic diseases, for which lifestyle interventions are considered the cornerstone of treatment. Dietary... (Review)
Review
Metabolic syndrome (MS) is associated with a range of chronic diseases, for which lifestyle interventions are considered the cornerstone of treatment. Dietary interventions have primarily focused on weight reduction, usually via energy restricted diets. While this strategy can improve insulin sensitivity and other health markers, weight loss alone is not always effective in addressing all risk factors associated with MS. Previous studies have identified diet quality as a key factor in reducing the risk of MS independent of weight loss. Additionally, supporting evidence for the use of novel strategies such as carbohydrate restriction and modifying the frequency and timing of meals is growing. It is well established that dietary assessment tools capable of identifying dietary patterns known to increase the risk of MS are essential for the development of personalised, targeted diet and lifestyle advice. The American Heart Association (AHA) recently evaluated the latest in a variety of assessment tools, recommending three that demonstrate the highest evidence-based and clinical relevance. However, such tools may not assess and thus identify all dietary and eating patterns associated with MS development and treatment, especially those which are new and emerging. This paper offers a review of current dietary assessment tools recommended for use by the AHA to assess dietary and eating patterns associated with MS development. We discuss how these recommendations align with recent and novel evidence on the benefits of restricting ultra-processed food and refined carbohydrates and modifying timing and frequency of meals. Finally, we provide recommendations for future redevelopment of these tools to be deployed in health care settings.
Topics: Delivery of Health Care; Diet; Dietary Carbohydrates; Humans; Metabolic Syndrome; Nutrition Assessment; Weight Loss
PubMed: 35458121
DOI: 10.3390/nu14081557 -
Current Cardiology Reviews Mar 2018Atherosclerosis is a progressive pathological process and a leading cause of mortality worldwide. Clinical research and epidemiological studies state that... (Review)
Review
CONTEXT
Atherosclerosis is a progressive pathological process and a leading cause of mortality worldwide. Clinical research and epidemiological studies state that atherosclerosis is caused by an amalgamation of metabolic and inflammatory deregulation involving three important pathological events including Endothelial Dysfunction (ED), Foam Cell Formation (FCF), and Vascular Smooth Muscle Cells (VSMCs) proliferation and migration.
OBJECTIVES
Research in recent years has identified Metabolic Syndrome (MS), which involves factors such as obesity, insulin resistance, dyslipidemia and diabetes, to be responsible for the pathophysiology of atherosclerosis. These factors elevate oxidative stress and inflammation-induced key signalling molecules and various microRNAs (miRs). In present study, we have reviewed recently identified molecular targets in the pathophysiology of atherosclerosis.
METHODS
Scientific literature obtained from databases such as university library, PubMed and Google along with evidences from published experimental work in relevant journals has been summarized in this review article.
RESULTS
The molecular events and cell signalling implicated in atherogenic processes of ED, FCF and VSMCs hyperplasia are sequential and progressive, and involve cross talks at many levels. Specific molecules such as transcription factors, inflammatory cytokines and chemokines and miRs have been identified playing crucial role in most of the events leading to atherosclerosis.
CONCLUSION
Studies associated with MS induced oxidative stress- and inflammation- mediated signalling pathways along with critical miRs help in better understanding of the pathophysiology of atherosclerosis. Several key molecules discussed in this review could be potent target for the prevention and treatment of atherosclerosis.
Topics: Atherosclerosis; Humans; Inflammation Mediators; Metabolic Syndrome; Oxidative Stress
PubMed: 28990536
DOI: 10.2174/1573403X13666171009112250 -
The Proceedings of the Nutrition Society Aug 2019Some food bioactives potentially exert anti-obesity effects. Anthocyanins (ACN), catechins, β-glucan (BG) and n-3 long chain PUFA (LCPUFA) are among the most promising... (Review)
Review
Some food bioactives potentially exert anti-obesity effects. Anthocyanins (ACN), catechins, β-glucan (BG) and n-3 long chain PUFA (LCPUFA) are among the most promising candidates and have been considered as a strategy for the development of functional foods counteracting body weight gain. At present, clinical trials, reviews and meta-analyses addressing anti-obesity effects of various bioactives or bioactive-rich foods show contradictory results. Abdominal obesity is an important criterion for metabolic syndrome (MetS) diagnosis along with glucose intolerance, dyslipidaemia and hypertension. Food bioactives are supposed to exert beneficial effects on these parameters, therefore representing alternative therapy approaches for the treatment of MetS. This review summarises outcomes on MetS biomarkers in recent clinical trials supplementing ACN, catechins, BG and n-3 LCPUFA, focusing mainly on anti-obesity effects. Overall, it is clear that the level of evidence for the effectiveness varies not only among the different bioactives but also among the different putative health benefits suggested for the same bioactive. Limited evidence may be due to the low number of controlled intervention trials or to inconsistencies in trial design, i.e. duration, dose and/or the method of bioactive supplementation (extracts, supplements, rich or enriched food). At present, the question 'Are bioactives effective in weight management and prevention of metabolic syndrome?' remains inconclusive. Thus, a common effort to harmonise the study design of intervention trials focusing on the most promising bioactive molecules is urgently needed to strengthen the evidence of their potential in the treatment of obesity, MetS and related diseases.
Topics: Anthocyanins; Anti-Obesity Agents; Catechin; Energy Metabolism; Fatty Acids, Omega-3; Humans; Metabolic Syndrome; Phytochemicals; beta-Glucans
PubMed: 30967168
DOI: 10.1017/S0029665119000545 -
Women's Health (London, England) 2024Across the globe, metabolic syndrome, hyperuric acid, and their related diseases, such as cardiovascular disease, diabetes, and insulin resistance, are increasing in... (Review)
Review
Across the globe, metabolic syndrome, hyperuric acid, and their related diseases, such as cardiovascular disease, diabetes, and insulin resistance, are increasing in incidence due to metabolic imbalances. Due to the pathogenesis, women are more prone to these diseases than men. As estrogen levels decrease after menopause, obesity and metabolic disorders are more likely to occur. Men are also affected by hyperuric acid. To provide ideas for the prevention and treatment of metabolic syndrome and hyperuricemia, this article reviews and analyzes the relationship between estrogen receptors, metabolic syndrome, and hyperuricemia.
Topics: Male; Humans; Female; Metabolic Syndrome; Receptors, Estrogen; Hyperuricemia; Insulin Resistance; Obesity
PubMed: 38420694
DOI: 10.1177/17455057241227362 -
Frontiers in Endocrinology 2024Metabolic syndrome (MetS) and sarcopenia (SP) have emerged as significant public health concerns in contemporary societies, characterized by shared pathophysiological...
BACKGROUND
Metabolic syndrome (MetS) and sarcopenia (SP) have emerged as significant public health concerns in contemporary societies, characterized by shared pathophysiological mechanisms and interrelatedness, leading to profound health implications. In this prospective cohort study conducted within a US population, we aimed to examine the influence of MetS and SP on all-cause and cardiovascular mortality.
METHODS
This study analyzed data from the National Health and Nutrition Examination Survey (NHANES) III for the years 1999-2006 and 2011-2018, and death outcomes were ascertained by linkage to National Death Index (NDI) records through December 31, 2019. Cox proportional hazard models were used to estimate hazard ratios (HRs) and 95% confidence intervals (95% CIs) for all-cause and cardiovascular mortality. In addition, subgroup and sensitivity analyses were conducted to test the robustness of the results.
RESULTS
Over a median follow-up period of 13.3 years (95% CI: 12.8-13.8), 1714 deaths were observed. The groups characterized by MetS-/SP+, MetS+/SP-, and MetS+/SP+ exhibited higher all-cause mortality rates in comparison to the MetS-/SP- group, with the MetS+/SP+ group (HR 1.76, 95% CI: 1.37-2.25) displaying the highest all-cause mortality. Increased cardiovascular mortality was observed in the MetS+/SP- (HR 1.84, 95% CI: 1.24-2.72), and MetS+/SP+ groups (HR 2.39, 95% CI: 1.32-4.35) compared to the MetS-/SP- group, whereas it was not statistically significant in the MetS-/SP+ group. However, among males and individuals aged < 60, the presence of both MetS and SP (MetS+/SP+ group) was found to be significantly associated with a higher risk of all-cause and cardiovascular mortality.
CONCLUSION
The coexistence of MetS and SP increased the risk of all-cause and cardiovascular mortality, particularly in males and in nonelderly populations. Individuals with either MetS or SP may require more careful management to prevent the development of other diseases and thereby reduce mortality.
Topics: Male; Humans; Metabolic Syndrome; Nutrition Surveys; Prospective Studies; Sarcopenia; Cardiovascular Diseases
PubMed: 38596221
DOI: 10.3389/fendo.2024.1346669 -
International Journal of Molecular... Mar 2020In the two decades since its discovery, a large body of evidence has amassed to highlight the potential of 3-iodothyronamine (T1AM) as an antiobesity drug, whose... (Review)
Review
In the two decades since its discovery, a large body of evidence has amassed to highlight the potential of 3-iodothyronamine (T1AM) as an antiobesity drug, whose pleiotropic signaling actions profoundly impact energy metabolism. In the present review, we recapitulate the most relevant properties of T1AM, including its structural and functional relationship to thyroid hormone, its endogenous levels, molecular targets, as well as its genomic and non-genomic effects on metabolism elicited in experimental models after exogenous administration. The physiological and pathophysiological relevance of T1AM in the regulation of energy homeostasis and metabolism is also discussed, along with its potential therapeutic applications in metabolic disturbances. Finally, we examine a number of T1AM analogs that have been recently developed with the aim of designing novel pharmacological agents for the treatment of interlinked diseases, such as metabolic and neurodegenerative disorders, as well as additional synthetic tools that can be exploited to further explore T1AM-dependent mechanisms and the physiological roles of trace amine-associated receptor 1 (TAAR1)-mediated effects.
Topics: Animals; Energy Metabolism; Humans; Metabolic Syndrome; Neurodegenerative Diseases; Receptors, G-Protein-Coupled; Thyronines
PubMed: 32183490
DOI: 10.3390/ijms21062005